MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor
Year: 2021
Type: conference-abstract
Source: Journal of Thoracic Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Seoul National University, Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Centre de Recherche en Cancérologie de Marseille, Indiana University Indianapolis, Indiana University School of Medicine, HealthONE, Washington University in St. Louis, Alvin J. Siteman Cancer Center, Roswell Park Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University, Duke Medical Center, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Amgen (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3120595252